ORLANDO, FL USA (UroToday.com) - Dr. Seth Lerner from Baylor College of Medicine presented his group’s findings from The Cancer Genome Atlas (TCGA) project.
ORLANDO, FL USA (UroToday.com) - The American Urological Association (AUA) guidelines recommend repeat TUR in patients with T1 tumors given the 30% risk of muscle invasive disease detection on re-staging.
ORLANDO, FL USA (UroToday.com) - Dr. Dan Theodorescu from the University of Colorado gave a “call to arms” for urologists to be aware of and develop biomarkers for bladder cancer.
ORLANDO, FL USA (UroToday.com) - Presented by Jeffrey J. Tomaszewski, Elizabeth Handorf, Charles W. Concodora, Reza Mehrazin, Alexander Kutikov, Rosalia Viterbo, David Y.T. Chen, Richard E. Greenberg, Robert G Uzzo, and Marc C. Smaldone at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA
ORLANDO, FL USA (UroToday.com) - Dr. Armin Soave presented some very interesting data regarding the presence of circulating tumor cells (CTCs) in patients undergoing radical cystectomy (RC) for bladder cancer. The premise of the study is that presence of CTCs is a harbinger of poorer oncologic outcomes and might be an indication for chemotherapy after radical cystectomy (RC).
ORLANDO, FL USA (UroToday.com) - Although BCG remains the intravesical therapy of choice, after TURBT, for high-grade non-muscle invasive bladder carcinomas (NMIBC), a recurrence and progression rate of up to 40% occurs after induction treatment. BCG failure likely can be attributed, at least partially, to inherent tumoral characteristics.
ORLANDO, FL USA (UroToday.com) - Cellular oxidative stress (COS), post BCG treatment, plays a central role in mediating direct effect of BCG on urothelial carcinoma (UC) cells.
ORLANDO, FL USA (UroToday.com) - Dr. Ashish M. Kamat presented data his group has been accumulating in an effort to predict response to BCG in patients with non-muscle invasive bladder cancer (NMIBC).
ORLANDO, FL USA (UroToday.com) - Inflammatory markers are known to predict outcomes in patients with hepatic, gastric, pancreatic, and kidney cancers. As such, authors sought to confirm initial data regarding the prognostic relevance of preoperative NLR for OS in patients undergoing RC for urothelial carcinoma of bladder.
ORLANDO, FL USA (UroToday.com) - As the urologic community works to embrace wide-spread and regular use of perioperative chemical venous thromboembolism (VTE) prophylaxis for inpatients, emerging data reveal that a large proportion of symptomatic VTE events after abdominal and pelvic cancer surgery occur following hospital discharge.
